Development of a type 2 diabetes risk model from a panel of serum biomarkers from the inter99 cohort

Diabetes Care

Volumn 32, Issue 7, 2009, Pages 1207-1212

  Kolberg, Janice A ^a   Jørgensen, Torben ^b,c   Gerwien, Robert W ^a   Hamren, Sarah ^a   McKenna, Michael P ^a   Moler, Edward ^a   Rowe, Michael W ^a   Urdea, Mickey S ^a   Xu, Xiaomei M ^a   Hansen, Torben ^d   Pedersen, Oluf ^c,d,e   Borch Johnsen, Knut ^d,e  

^a Tethys Bioscience   (United States)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d STENO DIABETES CENTER   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FERRITIN; GLUCOSE; INSULIN; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOASSAY; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; FERRITINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOASSAY; INSULIN; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RISK ASSESSMENT; RISK FACTORS;

EID: 67650070809     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1935     Document Type: Article

References (25)

1. Blonde L. State of diabetes care in the United States. Am J Manag Care 2007;13(Suppl. 2):S36-S40
2. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
3. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105
4. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167
5. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 2007;30:228-233
6. Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, Yazdi H, Booker L. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007;78:305-312
7. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein BE, Zimmet P, Shaw J. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 2008;371:736-743
8. Mohamed Q, Evans A. Retinopathy, plasma glucose, and the diagnosis of diabetes. Lancet 2008;371:700-702
9. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002;136:575-581
10. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068-1074
11. Glumer C, Vistisen D, Borch-Johnsen K, Colagiuri S. Risk scores for type 2 diabetes can be applied in some populations but not all. Diabetes Care 2006;29:410-414
12. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006;119:S10-S16
13. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002;51:1131-1137
14. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003;26:1745-1751
15. Jehn ML, Guallar E, Clark JM, Couper D, Duncan BB, Ballantyne CM, Hoogeveen RC, Harris ZL, Pankow JS. A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2007;165:1047-1054
16. American Diabetes Association. Diabetes 4-1-1: Facts, Figures, and Statistics at a Glance. Alexandria, VA, American Diabetes Association, 2005
17. Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 2003;10:377-386
18. Goldfine A, Patti ME, O'Shea S. Kolberg J, Gerwien R, McKenna M. Protein biomarkers in fasting serum samples correlate with diabetes risk factors (Abstract). Diabetes 2008;57:A410
19. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008;57:980-986
20. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334
21. Stentz FB, Kitabchi AE. Activated T lymphocytes in type 2 diabetes: implications from in vitro studies. Curr Drug Targets 2003;4:493-503
22. Kitabchi AE, Stentz FB, Umpierrez GE. Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochem Biophys Res Commun 2004;315:404-407
23. Pisinger C, Glumer C, Toft U, von Huth Smith L, Aadahl M, Borch-Johnsen K, Jorgensen T. High risk strategy in smoking cessation is feasible on a population-based level: the Inter99 study. Prev Med 2008;46:579-584
24. von Huth Smith L, Ladelund S, Borch-Johnsen K, Jorgensen T. A randomized multifactorial intervention study for prevention of ischaemic heart disease (Inter99): the long-term effect on physical activity. Scand J Public Health 2008;36:380-388
25. Toft U, Kristoffersen L, Ladelund S, Ovesen L, Lau C, Borch-Johnsen K, Pisinger C, Jørgensen T. The impact of a population-based multi-factorial lifestyle intervention on changes in long-term dietary habits: the Inter99 study. Prev Med. 2008;47:378-383